Advertisement

ASCO Guidelines Recommend Tamoxifen for 10 Years for Breast Cancer — Physician’s First Watch

Medical News |
May 28, 2014

ASCO Guidelines Recommend Tamoxifen for 10 Years for Breast Cancer

By Kelly Young

Edited by David G. Fairchild, MD, MPH , and Richard Saitz, MD, MPH, FACP, FASAM

Tamoxifen is now recommended for 10 years instead of just 5 for women with hormone receptor–positive breast cancer, according to new guidelines from the American Society of Clinical Oncology published in the Journal of Clinical Oncology. Studies have shown improved survival with extended tamoxifen, as well as reduced risk for recurrence and contralateral breast cancer.

Women who are pre- or perimenopausal should begin with 5 years of tamoxifen. After that, if they are still pre- or perimenopausal, they should take tamoxifen for another 5 years. If they have become postmenopausal, however, they should be given the choice of tamoxifen or an aromatase inhibitor for 5 years.

Women who are postmenopausal at diagnosis should be offered the choice of 10 years of tamoxifen, 5 years of an aromatase inhibitor, or either 2–3 or 5 years of tamoxifen followed by up to 5 years of an aromatase inhibitor.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement